Authors’ Disclosures
PDR, S. Kondo
ONCOLOGY
T. Shimizu reports personal fees from AbbVie, Chordia Therapeutics, Daiichi Sankyo, Chugai, IQVIA, Chugai, AbbVie, Daiichi-Sankyo, Eisai, Takeda Oncology, Taiho, and MSD; grants from AbbVie, Eli Lilly, LOXO Oncology, Novartis, Daiichi-Sankyo, Takeda Oncology, Bristol Myers Squibb, Eisai, Incyte, AstraZeneca, Pfizer, Chordia Therapeutics, Astellas, Symbio Pharmaceuticals, 3D-Medicine, PharmaMar outside the submitted work. M. Nishino reports personal fees from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim Japan, Chugai, Eli Lilly, MSD, Novartis, Pfizer, Ono, and Taiho outside the submitted work. Y. Nakamura reports grants and personal fees from Chugai; personal fees from Merck Biopharma, Guardant Health AMEA; grants from Taiho, Guardant Health, Genomedia, Daiichi Sankyo, Roche Diagnostics, and Seagen outside the submitted work. T. Koyama reports personal fees from Sysmex, Chugai, AstraZeneca; grants from AstraZeneca, Chugai, PACT Pharma, Novartis, Lilly, Takeda, Daiichi-Sankyo, and Zymworks outside the submitted work. S. Iwasa reports grants from Eisai during the conduct of the study; personal fees from Eisai; grants and personal fees from Ono Pharmaceutical Co., Ltd., and Bristol Myers Squibb outside the submitted work. K. Sudo reports personal fees from Eisai during the conduct of the study; personal fees from AstraZeneca, Pfizer, Nihon Medi-Physics; grants from NanoCarrier, Daiichi Sankyo, AstraZeneca, Pfizer, Amgen, PRA Health Sciences, Takeda, and Merck outside the submitted work. S. Kondo reports grants from Eisai outside the submitted work. K. Yonemori reports grants from Eisai during the conduct of the study; personal fees from Eisai and Eisai outside the submitted work; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Daiichi-Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Seattle Genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, Sanofi and Haihe: Clinical Trial fee for institution; Novartis, Astrazenca, Chugai Takeda, Genmab, Sanofi, OncXerna: consulting fee for personal; Pfizer, AstraZeneca, Eli lilly, Takeda, Chugai, MSD, FujiFilm Pharma, Bayer, Asteras, Boeringer Ingelheim, Daiichi Sankyo, Ono, Bristol Myers, PDR pharma, Sanofi for lecuture fees. K. Shitara reports grants and personal fees from Astellas Pharma, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Amgen, and MSD; personal fees from Bristol Myers Squibb, Takeda Pharmaceuticals, Novartis, Boehringer Ingelheim, Janssen, AstraZeneca; grants from Eisai, Syneos Health, PRA Health Sciences outside the submitted work. S. Shiono reports personal fees from Ono Pharmaceutical Co., Ltd. during the conduct of the study. D. Matsuoka reports personal fees from Eisai Co., Ltd. during the conduct of the study; personal fees from Eisai Co., Ltd. outside the submitted work. T. Suzuki reports personal fees from Eisai Co., Ltd. outside the submitted work; in addition, T. Suzuki has a patent to US20220117933A1 pending, a patent to WO2021/020336 pending, and a patent to TW202118486 pending. T. Takase is an employee of Eisai Co., Ltd. K. Yamaguchi reports personal fees from Eisai Co., Ltd. outside the submitted work. T. Semba reports personal fees from Eisai Co., Ltd. during the conduct of the study; personal fees from Eisai Co., Ltd. outside the submitted work; in addition, T. Semba has a patent to US11083705B2 issued, a patent to US20220117933A1 pending, a patent to WO2021/020336 pending, and a patent to TW202118486 pending. N. Yamamoto reports grants from Eisai during the conduct of the study; grants from Astellas, Chugai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, Toray, Kaken, InventisBio, Rakuten Medical; personal fees from Eisai, Takeda, Boehringer Ingelheim, CMIC Group, Chugai, ONO, Chugai, Daiichi-Sankyo, and Eisai outside the submitted work. No disclosures were reported by the other authors.